Integrated network pharmacology and experimental analysis unveil multi-targeted effect of 18α- glycyrrhetinic acid against non-small cell lung cancer.

Front Pharmacol

Virology and Oncology Lab, Department of Biotechnology, Jamia Millia Islamia, New Delhi, India.

Published: October 2022

AI Article Synopsis

  • Non-small cell lung cancer (NSCLC) is a highly aggressive cancer type, with increasing rates globally, prompting interest in anti-cancer therapies from traditional and natural sources that have low toxicity.
  • Recent research utilizes network pharmacology to identify 181 targets for 18α-Glycyrrhetinic acid (18α-GA), a compound from licorice, highlighting key targets like EGFR and AKT1 that may contribute to its anti-cancer effects.
  • Experimental studies demonstrate that 18α-GA can inhibit NSCLC cell growth through mechanisms such as cell cycle arrest and apoptosis, suggesting potential as a new treatment for NSCLC, but further research is needed for deeper understanding.

Article Abstract

Non-small cell lung cancer (NSCLC) is one of the most malignant types of cancer with soaring incidence rates worldwide, attributed to its heterogeneity and complex etiology. Evidently, alternative anti-cancer therapies comprising traditional medicines and natural products have gained attention for their ability to act as chemopreventive agents with minimal toxicities, either alone or in combination. Accumulating studies have substantiated the inevitability of network pharmacology studies for effectively mapping molecular targets of natural products against multifaceted diseases, including cancer. The 18α-Glycyrrhetinic acid (18α-GA), a triterpenoid found in licorice plants, has shown promising medicinal properties, although, its mechanism of action against NSCLC yet remains elusive. The present study was conducted to explore the anti- NSCLC potential of 18α-GA, employing integrative network pharmacology, molecular docking, and experimental research. Initially, network analysis revealed 181 common targets of 18α-GA in NSCLC as shown in the "compound-target- disease" network employing . Further analyses identified EGFR, AKT1, PI3KR1, MAPK1, IGF1, and SRC as the most crucial hub targets of 18α-GA against NSCLC. Moreover, molecular docking simulations and functional enrichment analyses indicated the involvement of multiple signaling pathways in suppressing NSCLC. Subsequent studies verified the antiproliferative effect of 18α-GA on two NSCLC cancer cell lines, H1299 and A549. Mechanistically, 18α-GA arrested cell cycle at the G1 phase, induced apoptosis, decreased migratory potential, and protein expression levels of EGFR-PI3K/AKT, as examined by flow cytometry, morphological assessment, RT-PCR, and western blot. In conclusion, this study delineates the therapeutic potential and underlying mechanism(s) of 18α-GA as a putative novel drug against NSCLC. However, further studies are warranted to elucidate the complete molecular mechanism(s) using animal models of NSCLC.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596789PMC
http://dx.doi.org/10.3389/fphar.2022.1018974DOI Listing

Publication Analysis

Top Keywords

network pharmacology
12
18α-ga nsclc
12
nsclc
9
non-small cell
8
cell lung
8
lung cancer
8
natural products
8
molecular docking
8
targets 18α-ga
8
18α-ga
7

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!